Health

  • |

    The Prior Authorization Desk Needs Prior Authorization

    ByHugh Jass

    I have reviewed the federal audit, and the document coughed before I did: Health Share of Oregon’s prior-authorization denial process was not consistently meeting the rules that make those denials lawful, timely, understandable, and properly reviewed. The HHS Office of Inspector General examined 100 Medicaid denials and found that 21 failed to comply with at least one federal or state requirement. This is the bureaucratic equivalent of a courthouse discovering its front door requires a permit.

    The failures were not confined to one ceremonial checkbox. OIG identified problems involving the expertise used to make decisions, the content of denial notices, the timing of those notices, language access, and communication with providers. In other words, the system responsible for explaining why care was denied sometimes struggled with the basic administrative duties required to explain a denial. Exhibit A had a pulse, and it was asking where Exhibit B went.

    OIG estimated that the findings could represent 5,677 noncompliant denials during calendar year 2023. That estimate does not mean every denial was improper, and the audit does not decide whether particular treatments were medically necessary. It identifies something more elemental and, in its own way, more haunting: the gatekeeper enforcing authorization rules did not consistently satisfy the rules governing its own decisions.

    The agency issued four recommendations to Health Share of Oregon. Those recommendations are the usual institutional medicine: review procedures, improve oversight, train the machinery, and make sure the paperwork behaves before it is allowed near another human life. Necessary, presumably. But somewhere in the records room, a form is being prepared for the denial department itself.

    Therefore, as a matter of administrative justice, the prior-authorization desk should submit its own application for prior authorization. It should demonstrate expertise, deliver a timely and understandable notice, provide language access, and consult the people who actually know what is happening. Until then, patients and providers are being asked to trust a stack of paperwork that the stack could not consistently complete correctly. The filing blinked first.

  • |

    The Public Helped Prove Remdesivir—Then Got the Invoice

    ByPhil McCracken

    I follow the invoice, and Remdesivir leads straight to the strangest line item in pandemic economics: public support helping carry the research risk while Gilead’s approximately $3,120 list-price headline arrives like the taxpayer has never met the taxpayer. That figure was not necessarily every patient’s final bill, and public funding did not pay for every step of the work. But the fairness problem remains plain: when public money helps steady the ladder, private billing should not act like it built the building alone.

    America gets cast as both venture capitalist and customer—asked to help finance the uncertain part, then sent shopping at the counter once the emergency treatment is ready. The money trail wore cologne, but the receipt still smells like a double charge: first as research backer, then as buyer. If public science helps make a medical breakthrough possible, why does the public receive so little leverage over the price and so much responsibility for paying it?

  • |

    Rod Stewart and the Luxury of Calling It Minor

    ByAmanda Lynn

    Rod Stewart’s Riverbend Music Center performance in Cincinnati was postponed after what was described as an “unforeseen but minor medical procedure,” and the word minor immediately began doing the work of a stadium roadie. The Associated Press later reported that Stewart underwent a coronary stent procedure, needed about four weeks to recover, and canceled the Cleveland performance along with the remaining dates on his “One Last Time” run. Recovery is the correct priority; nobody needs a rock star treating a doctor’s orders like an encore request.

    But “minor” is a fascinating word when it leaves the medical office and enters the fan inbox. For a physician, it may describe a routine procedure. For a person holding a ticket, it can mean rearranging travel, checking a hotel reservation, shifting a work schedule, and trying to understand whether the venue, promoter, ticket seller, or some mysterious digital cousin of all three has the next answer. The procedure may be small in the clinical sentence while becoming enormous in the calendar.

    Riverbend’s event information and promoter communications are left to carry the practical news about affected performances, which is how modern concertgoing turns a human health event into a relay race of notices. One cheerful update says postponed. Another says canceled. Somewhere, a fan is refreshing an account page with the haunted expression of someone who has paid in advance to become a part-time logistics coordinator.

    The target here is not Stewart, his heart, or his need to rest. The target is the soft language and fragmented ticketing system that make a major disruption sound like a gentle adjustment to the evening. Fans understand that health comes before a concert. They also deserve clear instructions about what happens next without having to assemble the answer from venue pages, promoter messages, ticket portals, and the spiritual residue of customer service.

    So let “minor” take its final bow. Medically routine can still be personally expensive, exhausting, and anything but minor to the person with a ticket, a hotel, a work shift, and an inbox full of automated reassurance. The song matters, absolutely. But when the tour stops, the invoice—and the explanation—should not be left waiting outside the venue.

  • |

    Public Grants, Private Tollbooth: Who Pays Twice for Xtandi?

    ByPhil McCracken

    At my invoice desk, the Xtandi money trail arrives wearing a lab coat and leaves in a limousine. The complaint is straightforward: public funding helped support UCLA-linked research, while commercialization and patent control became associated with Astellas and Pfizer. Then patients encountered annual U.S. price claims reaching roughly $160,000 to $180,000. That is a remarkable billing arrangement—taxpayers help finance the road, private interests control the toll gate, and the patient gets charged for driving on it.

    Not every stage of Xtandi’s development can be reduced to one public grant or one private decision, and a list price is not the same as every patient’s bill. But the public-return question remains as stubborn as a bad line item: when public science helps move an essential medicine forward, what does the public receive besides another invoice? Innovation may begin as public service, yet somehow ends as private property with a collections department. Follow the invoice long enough and it reaches the same destination: the patient, standing at the pharmacy counter with the receipt and no lobbyist’s expense account.

  • |

    The Drug-Price Mystery Has a Lobbying Budget

    ByPhil McCracken

    Patients receive a prescription bill written like a ransom note from an accountant, while the pharmaceutical industry’s Washington invoice arrives in plain English. Bloomberg Government reported that PhRMA spent $7.4 million lobbying in the second quarter of 2026, bringing its year-to-date total to $19.6 million. I have seen less money spent renovating an entire Capitol Hill office, although admittedly fewer people were trying to influence the rulebook.

    That spending does not, by itself, prove that lobbying caused any particular drug price or defeated any particular proposal. It does reveal something less mysterious: the trade group representing major pharmaceutical interests has a very clear budget for being present while everyone else debates why medicine costs so much. When an industry spends millions to participate in the policy conversation, “expertise” starts looking a lot like a reserved seat with better coffee.

    The timing is the whole money trail. Washington continued debating Medicare negotiation, most-favored-nation pricing, and other proposals aimed at lowering costs. Those are policy arguments, not settled outcomes, and they deserve scrutiny on their details. But patients are routinely told that drug pricing is too complex for ordinary people to understand, just as the people affected by the bill are asked to wait outside the room while well-funded representatives explain the machinery.

    That is the access economy in its natural habitat: the public gets a maze of rebates, formularies, negotiations, and carefully polished explanations; lobbyists get calendars, meetings, and a professional vocabulary for turning private interests into public homework. The pharmaceutical lobbying total reported by Bloomberg Government is not the entire industry’s spending, and it is not evidence of illegal conduct. It is simply a large, legible number attached to an argument that is often presented as impossibly complicated.

    So Washington keeps searching for the missing answer to drug prices. Meanwhile, the money trail has already found the billing department. Patients get the mystery, lobbyists get the appointment calendar, and taxpayers get another explanation for why reform remains under review.

    Sources

  • |

    The CDC’s Autism Page Is Doing the ‘Just Asking Questions’ Fog Machine

    ByHolden McGroin

    My corkboard has identified a new suspect in the vaccine misinformation loop: the CDC communications department, apparently operating a fog machine with a government email address. The agency’s revised autism page reopens uncertainty around vaccines, while its separate MMR safety page says many carefully performed studies found no link between MMR vaccination and autism. That is not clarity. That is two official webpages standing in the hallway, pointing at each other, while parents are told to bring their own flashlight.

    The contradiction matters because public-health guidance is supposed to reduce confusion, not make ordinary people perform a graduate seminar between school pickup and dinner. The autism page says the claim that vaccines do not cause autism is not evidence-based, according to the CDC’s current language, while also retaining a citation to a hepatitis B study reported by NOTUS as retracted and methodologically problematic. A retracted study should not be treated like a fresh clue in a detective novel unless the detective is selling supplements on a livestream.

    Meanwhile, the CDC’s MMR page presents the more familiar evidence-based position: many carefully performed studies found no link between MMR vaccination and autism. Those pages do not create a productive scientific debate for families. They create a credibility crisis for the institution that is supposed to explain what is known, what is uncertain, and what has been discredited. The algorithm, naturally, sees only engagement potential. Every official wobble becomes premium content for rumor accounts, influencers, and anyone whose business model requires the public to stay permanently alarmed.

    Associated Press coverage reported political responses and Senate scrutiny surrounding the CDC’s revised language. That response is part of the larger problem: scientific communication starts looking like political collateral, edited according to whichever faction is currently demanding a dramatic question mark. The beneficiaries are not the families stuck sorting claims from evidence. They are the panic merchants, who get to convert institutional ambiguity into clicks, subscriptions, and another exhausting group-chat emergency.

    The CDC did not merely fail to clear the smoke. It appears to be revising the fog machine’s instruction manual while insisting everyone remain calm. People deserve public-health agencies that can acknowledge uncertainty without laundering discredited material or contradicting their own guidance. Follow the thread, sure—but check the knot before somebody charges admission to the maze.

  • |

    ChatGPT Wants Your Medical Records, But Not the Responsibility

    ByLee Keybum

    Lee Keybum reads the terms so you do not have to, and OpenAI’s new Health feature comes with a very modern trust bargain: ChatGPT can become familiar with your connected medical records, lab results, prescriptions, Apple Health data, and health conversations, but it still wants to be treated as support rather than medical care. OpenAI announced the U.S. rollout on July 23, describing Health in ChatGPT as a place for personalized guidance and health-related conversations. That is a lot of intimate information to hand to a general-purpose chatbot before it politely reminds you that it is not intended to diagnose or treat anything.

    The contradiction is not hidden; it is laminated into the product. The more information ChatGPT can use, the more naturally it can sound like the friend who knows why every pill is in the cabinet and which lab result made you stare at the ceiling. But OpenAI says the service does not replace qualified medical professionals. In ordinary-person language, the platform wants the context required to sound medically informed while preserving an escape hatch if the conversation wanders into actual medical responsibility.

    OpenAI’s health privacy policy also says connected health data is not used to train its foundation models or target ads by default. That matters, and “by default” matters too. It is not a promise that every possible privacy concern has evaporated into the cloud. It means the company’s stated bargain is narrower: users may authorize sensitive data connections for the feature, while OpenAI says those connections are treated differently from ordinary ChatGPT data for model training and advertising.

    For users, the practical question is not whether the chatbot can produce a soothing paragraph about wellness. It is whether convenience quietly turns the app into the most informed entity in a person’s medical life without giving that entity the accountability people normally expect from medical care. A doctor has credentials, professional rules, and a human being attached to the decision. ChatGPT has a privacy policy, a disclaimer, and a remarkable talent for making a sentence sound settled before the facts are.

    That is the subscription-barnacle version of artificial intelligence: first it asks for your bloodwork, sleep history, medication list, and trust; then, if the answer is wrong, it becomes a very confident autocomplete with no medical license. OpenAI may call Health a support tool, but the user experience is built to feel personal and informed. The company wants the data that makes the system sound like a doctor while keeping the responsibility label safely out of frame.

  • |

    The Miracle Arrives With a $3.2 Million Invoice

    ByPhil McCracken

    Here is the money trail presented by the scenario: children’s-hospital and academic micro-dystrophin research tied to Nationwide Children’s Hospital moves into Sarepta’s private commercialization pipeline, and the number waiting at the end is $3.2 million. Nationwide is presented as receiving licensing and royalty revenue; families and payers are presented as facing the cost. That is a remarkable invoice-routing system: the science gets described as a shared triumph, while the people who need it are treated like they wandered into the pricing meeting without a badge.

    Profit is not the villain. Pretending the public-private pipeline ends at “innovation” is. If the figure and licensing arrangement are accurate as presented, the contradiction is hard to miss: the breakthrough gets inspirational music, the commercial deal gets revenue, and the family gets a financial document written in the ancient language of “please indicate which organ you’d like to sell first.” Nobody has to oppose useful medicine or licensing to ask why the people carrying the medical and financial risk get no meaningful seat at the pricing table.

  • |

    Medicare’s Taxpayer-Funded Layaway Plan

    ByHarlan Quill

    At the courthouse-basement level of policy math, the arrangement is hard to defend: taxpayers help absorb the early risk of medical discovery, then a private patent can put the finished medicine behind a padlock while Medicare and patients meet the checkout price.

    That is a taxpayer-funded layaway plan. We help finance the scientific groundwork, a company controls the bottle, and the public returns to retrieve its medicine with a bill wearing a shareholder-return hat. If public support helps make a breakthrough possible, public policy should at least ask what public value comes back. Otherwise, we did not merely buy the breakthrough; we rented it back from the company that put a padlock on the bottle.

  • |

    Medicare Paid More Than the Bill, Because Apparently Even the Bill Needs Oversight

    ByHugh Jass

    I have spent the morning exhuming a HHS-OIG audit, and the document coughed. The review examined 801 selected Medicare Part B claim lines from payments made in 2022 and 2023. Among them were 138 incorrect lines that produced at least $140,182 in overpayments. Another 31 lines, totaling $76,640, lacked supporting documentation. This is not proof that every claim was improper; it is a selected sample with enough administrative thunder to make the filing cabinet nervous.

    The target here is not patients or an accusation that providers acted intentionally. The target is the payment-control machinery: the edits, reviews, and safeguards assigned to notice when Medicare money is headed somewhere it should not go. Wisconsin Physicians Service Insurance Corporation already had system edits and follow-up procedures intended to identify overpayments. HHS-OIG still found incorrect payments and unsupported claim lines in the reviewed sample, which suggests the controls were present in the same way a smoke detector is present during a very organized kitchen fire.

    Hugh Jass Serious Investigative Reporting has located the central contradiction: the claim was important enough to generate edits, reviews, and recommendations, but not important enough to stop the money first. The system had a process for checking the paperwork, a process for checking the checking, and apparently a later process for discovering that the first two processes had allowed the money to leave the building wearing sunglasses.

    HHS-OIG recommended corrective action, and WPS concurred with those recommendations. The audit does not establish a recovery outcome, so the responsible sentence ends there. That restraint is called evidence, a rare substance often found in the same room as a spreadsheet but never invited to the budget meeting.

    The invoice, in other words, survived quality control by becoming a payment. Before the money moved, the bill was suspicious. After the money moved, it appears to have received diplomatic immunity. Medicare oversight is supposed to catch mistakes; in this case, the auditors had to audit the audit trail, proving once again that paperwork is not useless. It is merely waiting for another layer of paperwork to explain why it failed.

End of content

End of content